Sangamo Therapeutics Appoints John Markels to Its Board of Directors
February 12 2020 - 8:00AM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced the appointment of Dr. John Markels, an
accomplished pharmaceutical executive with three decades of general
management, manufacturing and technology experience at Merck, to
the Sangamo Board of Directors.
"We are very pleased to welcome John to our Board," said Sandy
Macrae, Chief Executive Officer of Sangamo. “John’s manufacturing
expertise and global general management and therapeutic area
leadership experience will greatly benefit Sangamo as we build out
our own in-house gene and cell therapy manufacturing capabilities
and advance our innovative pipeline of genomic medicine product
candidates toward registration and eventual commercialization.”
Dr. Markels has over 30 years of leadership experience in the
pharmaceutical industry. He currently serves as President of Global
Vaccines at Merck, a role in which he leads an integrated team
dedicated to discovery and development, supply and access, and
global marketing and long-term strategy for the vaccines portfolio.
Earlier roles at Merck included President, Latin America, as well
as a long career in senior leadership positions in major regions
worldwide in manufacturing technology, operations and strategy,
business development, alliance management, and supply chain. Dr.
Markels received his Ph.D. in chemical engineering from the
University of California, Berkeley and his B.S. in chemical
engineering from the University of Delaware.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and genome regulation. For more
information about Sangamo, visit www.sangamo.com.
Forward Looking Statements
This press release contains or refers to forward-looking
statements regarding Sangamo's current expectations. These
forward-looking statements include, without limitation, statements
regarding the potential benefits of cell therapy, the Company's
ability to develop and commercialize product candidates to address
genetic diseases with the Company's proprietary technologies and
the timing of commencement or next stages of such programs and the
anticipated benefits therefrom. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Actual
results may differ from those projected in forward-looking
statements due to risks and uncertainties that exist in Sangamo's
operations and business environments. These risks and uncertainties
are described more fully in Sangamo's Annual Report on Form 10-K
for the year ended December 31, 2018 as filed with the Securities
and Exchange Commission on March 1, 2019 and Sangamo's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2019 that
it filed on November 6, 2019. Forward-looking statements contained
in this announcement are made as of this date, and Sangamo
undertakes no duty to update such information except as required
under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200212005263/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Investor Relations and Media Inquiries –
European Union & United Kingdom Caroline Courme 33 4 97
21 27 27 ccourme@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024